Seres Therapeutics Inc logo

Seres Therapeutics Inc

$ 6.42 +0.29 (+4.73%) 04:00 PM EST
P/E:
At Loss
P/B:
26.00
Market Cap:
$ 852.41M
Enterprise V:
$ 641.97M
Volume:
2.08M
Avg Vol (2M):
1.06M
Also Trade In:
Volume:
2.08M
Market Cap $:
852.41M
PE Ratio:
At Loss
Avg Vol (2-Month):
1.06M
Enterprise Value $:
641.97M
PB Ratio:
26.00
GF Score:
Year:
Embed
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download

Business Description

Description
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
Name Current Vs Industry Vs History
Cash-To-Debt 2.54
Equity-to-Asset 0.08
Debt-to-Equity 3.35
Debt-to-EBITDA -0.83
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -2.11
Distress
Grey
Safe
Beneish M-Score -1.34
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 46.71
9-Day RSI 48.89
14-Day RSI 52.12
6-1 Month Momentum % -30.52
12-1 Month Momentum % -23.79

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 2.35
Quick Ratio 2.35
Cash Ratio 2.2
Days Sales Outstanding 4.55

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -30.9

Financials (Next Earnings Date:2022-11-10 Est.)

MCRB's 30-Y Financials

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:MCRB

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
To

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Embed

Valuation Box

Year:
Embed

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 136.655
EPS (TTM) ($) -1.14
Beta 3.12
Volatility % 105.54
14-Day RSI 52.12
14-Day ATR ($) 0.427511
20-Day SMA ($) 6.298
12-1 Month Momentum % -23.79
52-Week Range ($) 2.5 - 11.69
Shares Outstanding (Mil) 124.07

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Seres Therapeutics Inc Filings

Document Form Filing Date
No Filing Data

Seres Therapeutics Inc Analysis

Share your research

Headlines

See More
No news.